<DOC>
	<DOCNO>NCT01139203</DOCNO>
	<brief_summary>Entecavir demonstrate superior virologic biochemical benefit lamivudine adefovir . The investigator evaluate effect entecavir combine Hepatitis B immune globulin ( HBIG ) lamivudine adefovir combine HBIG Chinese liver transplantation patient Hepatitis B Virus ( HBV ) relate disease .</brief_summary>
	<brief_title>Prophylaxis Hepatitis B Virus Recurrence After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1. patient transplant wait list HBVrelated liver disease . 2 . HBsAgpositive . 3. serum HBVDNA negative . 4. HCV , HDV HIV coinfection . 5. without renal dysfunction . 6 . No lamivudine , adefovir entecavir drug allergy history . 7. HBVYMDD mutation patient longterm use lamivudine . 1. patient HBVrelated hepatocellular carcinoma beyond Milan criterion . 2 . HBsAgnegative . 3. serum HBVDNA positive . 4 . HCV , HDV HIV coinfection . 5. patient severe renal dysfunction failure . 6. lamivudine , adefovir entecavir drug allergy history . 7 . HBVYMDD mutation patient longterm use lamivudine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HBV recurrence</keyword>
	<keyword>entecavir</keyword>
</DOC>